Noticias y Actividades de Medicinova

Medicinova es una empresa que cotiza bajo el símbolo de cotización MNOV (US).

Ver el organigrama con sus 7 ejecutivos principales

Biografías más buscadas en Medicinova

• Yuichi Iwaki, Director, President and Chief Executive Officer
• Hideki Nagao, Director
• Nicole Lemerond, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Medicinova.

Medicinova tiene 2.406 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y BioNTech (Alemania).

Popular M&A news in Biotecnología

• Oak Hill Bio acaba de anunciar una recaudación de fondos de 33 millones de dólares. (publicado el 4 de junio de 2026).
• IMU Biosciences acaba de anunciar una recaudación de fondos de 53 millones de dólares. (publicado el 3 de junio de 2026).
• NewLimit acaba de anunciar una recaudación de fondos de 435 millones de dólares. (publicado el 3 de junio de 2026).

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Valerie Hanote - Non-Executive Director en Eurofins

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Medicinova

• MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology | MediciNova, Inc.
• MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada | MediciNova, Inc.
• MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria | MediciNova, Inc.
• MediciNova Receives Gene Therapy Milestone Payment | MediciNova, Inc.
• MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury | MediciNova, Inc.
• MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe | MediciNova, Inc.
• MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe | MediciNova, Inc.
• MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology | MediciNova, Inc.
• MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe | MediciNova, Inc.
• MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting | MediciNova, Inc.
• View more press releases Close

Redes sociales sobre Medicinova

• Medicinova en Wikipedia, Google News y Yahoo Finance
• Medicinova en LinkedIn, Twitter y YouTube